A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1649 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Tekturna | Novartis Pharmaceuticals Corporation | Light-pink, biconvex round tablet | Oral route | Renin inhibitor | Renin |
| 1650 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Tekturna HCT | Novartis Pharmaceuticals Corporation | Biconvex, ovaloid film-coated tablets. | Oral route | Renin inhibitor | Renin |
| 1651 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Tekamlo | Novartis Pharmaceuticals Corporation | Tablets (aliskiren/amlodipine): 150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg, 300 mg/10 mg | Oral route | Renin inhibitor | Renin |
| 1652 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Amturnide | Novartis Pharmaceuticals Corporation | Tablets (aliskiren/ amlodipine/ HCTZ): 150/5/12.5, 300/5/12.5, 300/5/25, 300/10/12.5, 300/10/25 mg. | Oral route | Renin inhibitor | Renin |
| 1654 | Th1150 | Secukinumab | Secukinumab Heavy Ch Full view | 672 | IIa | Immunological | Cosentyx | Novartis Pharmaceuticals Corporation | Sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution. | Subcutaneous injection | Inhibitor | IL-17A cytokine |
| 1661 | Th1153 | Alefacept | Heavy Chain: CFSQQIY Full view | 705 | IIa | Immunological | Amevive | Astellas Pharma Inc. | Sterile, white-to-off-white, preservative-free, lyophilized powder | Intramuscular Injection | Dermatologic and Immunosupressive agents | T-cell surface antigen CD2, Complement C1r subcomponent, Complement C1q subcomponent subunit A, B, C, Low affinity immunoglobulin gamma Fc region receptor III-A,III-B, II-a, II-b, II-c |
| 1667 | Th1158 | Aprotinin | RPDFCLEPPYTGPCKARIIR Full view | 58 | IIa | Immunological | Trasylol | Bayer Pharmaceuticals | Clear, colorless, sterile isotonic solution | Intravenous administration | N.A. | Trypsin-1, Chymotrypsinogen B, Plasminogen, Kallikrein-! |
| 1703 | Th1167 | Atezolizumab | NA Full view | 0 | IIa | Cancer | Tecentriq | NA | NA | NA | NA | NA |
| 1741 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | NA | NA | Injection, Solution; Injection | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 9 |
| 1742 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 10 |
| 1743 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Canada Inc | Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 11 |
| 1744 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 12 |
| 1797 | Th1191 | Vedolizumab | Heavy Chain Sequence Full view | 716 | IIa | Immunological Disorders | Entyvio | Takeda Pharmaceuticals America, Inc. | Injection, Powder, Lyophilized, for Solution | Intravenous | Immunosupressive agent, Antineoplastic agent | Integrin alpha-4, Integrin beta-7 |
| 1802 | Th1196 | Siltuximab | Heavy Chain Sequence Full view | 708 | IIa | Immunological Disorders | Sylvant | Janssen Inc | Lyophilized Powder | Intravenous infusion | Antineoplastic and Immunomodulating Agents, Immunosuppressive Agents | Interleukin-6 |
| 1826 | Th1216 | Anthrax immune globulin human | NA Full view | 0 | IIa | Immunological Disorders | ANTHRASIL | Cangene Corporation | Liquid | Intravenous | Plasma derivative | Protective antigen |
| 1830 | Th1220 | Brodalumab | NA Full view | 0 | IIa | Immunological Disorders | Siliq | NA | sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution | Subcutaneous | Antineoplastic and Immunomodulating Agents | Interleukin 17 receptor A |
| 1831 | Th1221 | C1 Esterase Inhibitor (Recombinant) | NA Full view | 0 | IIa | Cardiac Disorders | Ruconest | Tjoapack Netherlands Bv | Powder and liquid for solution | Intravenous | Blood and Blood Forming Organs | Complement C1r subcomponent, Complement C1s subcomponent, Plasma kallikrein, Coagulation factor XII, Prothrombin, Coagulation factor XI, Tissue-type plasminogen activator |
| 1832 | Th1222 | Canakinumab | H-GAMMA-1 Chain: QVQ Full view | 842 | IIa | Immunological Disorders | Ilaris | Novartis | Lyphilized powder | Subcutaneous | Antineoplastic and Immunomodulating Agents | Interleukin-1 beta |